# Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer

> **NCT03192059** · PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 43 (actual)

## Conditions studied

- Cervical Cancer
- Endometrial Cancer
- Uterine Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Radiation
- **DRUG:** Vitamin D
- **DRUG:** Aspirin
- **DRUG:** Lansoprazole
- **DRUG:** Cyclophosphamide
- **DIETARY_SUPPLEMENT:** Curcumin

## Key facts

- **NCT ID:** NCT03192059
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2021-09-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03192059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03192059, "Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03192059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*